Journal of aerosol medicine and pulmonary drug delivery · 2025
Exploratory Pharmacokinetic Study of Pegylated Interferon Alfa-2b Aerosolized Inhalation Administration.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chu Hongran, Wu Hanzhou, Zou Fenfang, Yin Yalin
Аннотация
OBJECTIVE: This study aimed to compare the pharmacokinetics and tissue distribution of aerosolized pegylated interferon α-2b (PEG IFNα-2b) with standard interferon α-2b (IFNα-2b) in an animal model, paving the way for further investigation into their pharmacodynamics.
METHODS: Fifty-six Sprague Dawley rats were divided into 14 groups receiving either PEG IFNα-2b or standard IFNα-2b via aerosolized inhalation into the lower respiratory tract. Each group received a single dose of consistent concentration and volume. Pharmacokinetic parameters such as Cmax, Tmax, t1/2, AUC(0-t), and MRT(0-t) were evaluated through blood samples and tissue dissection at specified time intervals post-administration.
RESULTS: Analysis revealed significantly higher AUC(0-t) and MRT(0-t) in the lungs, trachea, and bronchi of the PEG IFNα-2b group compared to the standard IFNα-2b group (p < 0.05), with minimal systemic exposure.
CONCLUSION: Aerosolized PEG IFNα-2b demonstrated increased drug exposure and retention in the lower respiratory tract compared to standard IFNα-2b, suggesting potential therapeutic advantages such as reduced dosing frequency. Further studies are warranted to explore enhanced clinical outcomes.
METHODS: Fifty-six Sprague Dawley rats were divided into 14 groups receiving either PEG IFNα-2b or standard IFNα-2b via aerosolized inhalation into the lower respiratory tract. Each group received a single dose of consistent concentration and volume. Pharmacokinetic parameters such as Cmax, Tmax, t1/2, AUC(0-t), and MRT(0-t) were evaluated through blood samples and tissue dissection at specified time intervals post-administration.
RESULTS: Analysis revealed significantly higher AUC(0-t) and MRT(0-t) in the lungs, trachea, and bronchi of the PEG IFNα-2b group compared to the standard IFNα-2b group (p < 0.05), with minimal systemic exposure.
CONCLUSION: Aerosolized PEG IFNα-2b demonstrated increased drug exposure and retention in the lower respiratory tract compared to standard IFNα-2b, suggesting potential therapeutic advantages such as reduced dosing frequency. Further studies are warranted to explore enhanced clinical outcomes.